CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Adverse drug reactions - Management
Basis for recommendation
- The Yellow Card scheme is operated by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines.
- The MHRA has issued the recommendations [MHRA, 2006a; MHRA, 2006b]:
- For protecting patient confidentiality.
- For increasing the rate of reporting of suspected ADRs by [Independent Steering Committee, 2004]:
- Expanding reporting to healthcare professionals and the members of the public.
- Improving access to reporting by offering both electronic and non-electronic routes for submitting reports.
© NHS Institute for Innovation and Improvement